Board Member
Biomarin Pharmaceutical Inc (BMRN)Equibles does not estimate personal net worth.
Get an email with a short summary when Biomarin Pharmaceutical Inc publishes a filing, an earnings call transcript or a press release.
Get BMRN alertsAlexander Hardy is recorded as Board Member at Biomarin Pharmaceutical Inc (BMRN) since December 1, 2023 and CEO at Biomarin Pharmaceutical Inc (BMRN). The newest filing on record that lists Alexander Hardy as CEO at Biomarin Pharmaceutical Inc (BMRN) is dated April 21, 2026. Biomarin Pharmaceutical Inc reported in an 8-K filed November 3, 2023 that Alexander Hardy was appointed member of the Board, effective December 1, 2023. Biomarin Pharmaceutical Inc reported in an 8-K filed November 3, 2023 that Alexander Hardy was appointed President and Chief Executive Officer, effective December 1, 2023. The proxy statement of Biomarin Pharmaceutical Inc reports total compensation of $21,927,563 for Alexander Hardy in fiscal 2025, including a base salary of $1,130,769. Disclosed compensation is on record for 3 fiscal years. Alexander Hardy has spoken on 12 earnings calls across 1 company, most recently for Biomarin Pharmaceutical Inc on November 2, 2026. Biomarin Pharmaceutical Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Biomarin Pharmaceutical Inc includes Richard A. Meier (Chairman), Brian Mueller (CFO), Daniel Spiegelman (CFO) and 7 others.
“On November 1, 2023, the Company announced the appointment of Alexander Hardy, age 55, to serve as the Company's President and Chief Executive Officer and as a member of the Board, effective as of December 1, 2023 (the "Effective Date").”
“On November 1, 2023, the Company announced the appointment of Alexander Hardy, age 55, to serve as the Company's President and Chief Executive Officer and as a member of the Board, effective as of December 1, 2023 (the "Effective Date").”
“Starting on slide five, strong demand across our diversified portfolio of innovative therapies drove 32% year-over-year growth in the third quarter, surpassing $1 billion in quarterly revenues for the first time in our history.”
“Starting on slide five, Baymarin delivered a standout second quarter, combining strong growth to nearly $1 billion in revenue with the successful close and integration of Amicus while delivering on milestones that strengthen our leadership in genetic conditions.”
“I am so pleased that we completed the Amicus acquisition last week, starting a new and exciting chapter for Biomarin with the addition of two innovative therapies, Gallifold for Fabray disease and Pombility and Opfolder for Pompe disease.”
“Thank you all for joining us today to discuss Biomarine's fourth quarter and full year 2025 results, as well as our outlook for 2026, which will be an exciting year.”
“Starting on slide five, I am very pleased with the strong results across the business, leading us to raise four-year total revenues guidance at the midpoint and reaffirm our Voxogo revenue outlook for 2025.”
2023-12-01–present
Start not stated–present
Last confirmed April 21, 2026
Biotechnology · Healthcare
CEO, Board Member
2023-12-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Biomarin Pharmaceutical Inc (BMRN) | President and CEO | $1,130,769 | $21,927,563 |
| 2024 | Biomarin Pharmaceutical Inc (BMRN) | President and CEO — | $1,050,000 | $14,853,605 |
| 2023 | Biomarin Pharmaceutical Inc (BMRN) | President and CEO — | $64,615 | $17,875,236 |
